Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ONT-10 |
Synonyms | |
Therapy Description |
ONT-10 is a cancer vaccine that consists of encapsulated glycoprotein MUC1 and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A, which may lead to immune stimulation and antitumor effects (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ONT-10 | ONT-10 is a cancer vaccine that consists of encapsulated glycoprotein MUC1 and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A, which may lead to immune stimulation and antitumor effects (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02270372 | Phase I | Varlilumab ONT-10 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | Completed | USA | 0 |